Arcus Biosciences (RCUS) Operating Margin (2017 - 2026)

Arcus Biosciences' Operating Margin history runs 10 years deep, the most recent figure standing at 788.24% for Q1 2026.

• In Q1 2026, Operating Margin fell 35252.0% year-over-year to 788.24%; the TTM figure through Mar 2026 stood at 168.64% (up 14058.0% YoY), while the FY2025 annual figure was 156.28%, down 2837.0% from the prior year.
• Operating Margin for Q1 2026 stood at 788.24%, down from 345.45% in the prior quarter.
• The five-year high for Operating Margin was 5.0% in Q2 2025, with the low at 788.24% in Q1 2026.
• The 5-year median for Operating Margin is 286.21% (2023), against an average of 329.77%.
• The sharpest annual moves came in 2022 and 2023: Operating Margin surged 61375 bps in 2022, then plunged 43235 bps in 2023.
• Arcus Biosciences' Operating Margin stood at 217.65% in 2022, then sank by 199 bps to 650.0% in 2023, then jumped by 39 bps to 396.15% in 2024, then gained by 13 bps to 345.45% in 2025, then slumped by 128 bps to 788.24% in 2026.
• Business Quant data shows RCUS's Operating Margin at 788.24% in Q1 2026, 345.45% in Q4 2025, and 546.15% in Q3 2025.